Home / FlashMed

FlashMed

Titolo Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
Autore Kamyar Kalantar-Zadeh, MD, MPH, PhD,1,2 Grace H. Lee, PharmD,3 Jessica E. Miller, MPH,1,2 Elani Streja, MPH,1,2 Jennie Jing, MS,1 John A. Robertson, MD,4 and Csaba P. Kovesdy, MD5
Referenza Am J Kidney Dis 2009; 53:823-834
Contenuto Background: Identification of predictors of hyporesponsiveness to erythropoietin-stimulating agents (ESAs) in hemodialysis (HD) patients may help improve anemia management and reduce hemoglobin level variability. Study Design: We conducted repeated-measure and logistic regression analyses in a retrospective cohort of long-term HD patients to examine the association of iron markers and measures of renal osteodystrophy with ESA responsiveness. The ESA response coefficient at the individual level, ie, the least confounded dose-response association, was separated from the population level, assumed to represent confounding by medical indication. Setting/Participants: The national database of a large dialysis organization (DaVita Inc, El Segundo, CA) with 38,328 surviving prevalent HD patients during 12 months who received ESA for at least 3 consecutive calendar quarters was examined. Predictors: Serum levels of ferritin, iron saturation ratio, intact parathyroid hormone, and alkaline phosphatase. Outcomes/Other Measurements: The main outcome was case-mix-adjusted hemoglobin response to quarterly averaged ESA dose at the individual level. The odds ratio (OR) of the greatest versus poorest ESA-response quartile at the patient level was calculated. OR less than 1.0 indicated ESA hyporesponsiveness, and OR greater than 1.0, enhanced responsiveness. Results: Mean ESA-response coefficients of the least to most responsive quartiles were 0.301 _0.033 (SD), 0.344 _ 0.004, 0.357 _ 0.004, and 0.389 _ 0.026 g/dL greater hemoglobin level per 1,000 U/wk greater ESA dose in each quarter, respectively. The ORs of greatest versus poorest ESA responsiveness at the patient level were serum ferritin level less than 200 ng/mL (0.77; 95% confidence interval [CI], 0.70 to 0.86; reference, 200 to 500 ng/mL), iron saturation ratio less than 20% (0.54; 95% CI, 0.49 to 0.59; reference, 20% to 30%), intact parathyroid hormone level of 600 pg/mL or greater (0.54; 95% CI, 0.49 to 0.60; reference, 150 to 300 pg/mL), and alkaline phosphatase level of 160 IU/L or greater (0.64; 95% CI, 0.58 to 0.70; reference, 80 to 120 IU/L). Lower estimated dietary protein intake and serum levels of nutritional markers were also associated with greater risk of ESA hyporesponsiveness. Limitations: Our results may incorporate uncontrolled confounding. Achieved hemoglobin level may have different associations than targeted hemoglobin level. Conclusions: In long-term HD patients, low iron stores, hyperparathyroidism, and high-turnover bone disease are associated with significant ESA hyporesponsiveness. Prospective studies are needed to verify these associations.
Data 11.05.2009
 
Maggiori informazioni   
Lista completa